Kymera Therapeutics Inc Stock News

Kymera Therapeutics, Inc. ( KYMR ) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Jared Gollob - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Well, thank you, everyone, for joining us in our fireside chat with Kymera...

Kymera Therapeutics, Inc. ( KYMR ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Co-Founder, President, CEO & Director Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Marc Frahm - TD Co...

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November 4, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jared Gollob - Chief Medical Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Good afternoon, everyone.

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jared Gollob - Chief Medical Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Here we go. So welcome to the seco...

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two ...